Shares of Agios Pharmaceuticals experienced a dramatic decline of approximately 45% during premarket trading on Wednesday following the announcement of mixed results from a late-stage trial...
Gilead Sciences announced on March 15, 2024, that its Phase 3 clinical trial for the antibody-drug conjugate Trodelvy did not meet its primary endpoint. The trial...
AstraZeneca has announced significant progress in the development of a new blood pressure therapy, achieving its primary endpoint in a Phase 3 clinical trial. This breakthrough...
Regeneron Pharmaceuticals announced on October 25, 2023, that its investigational treatment, garetosmab, successfully met the primary endpoint in a Phase 3 clinical trial. This trial focused...
Shares of Abivax experienced a remarkable increase of over 400% on October 25, 2023, following the announcement of significant progress in its late-stage trials for obefazimod,...
